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Apart from ATP synthesis mitochondria have many other functions, one being nitrite
reductase activity. Nitric oxide (NO) released from nitrite has been shown to protect
the heart from ischemia/reperfusion (I/R) injury in a cGMP-dependent manner. However,
the exact impact of mitochondria on the release of NO from nitrite in cardiomyocytes
is not completely understood. Besides mitochondria, a number of non-mitochondrial
metalloproteins have been suggested to facilitate this process. The aim of this study
was to investigate the impact of mitochondria on the bioactivation of nitrite in HL-1
cardiomyocytes. The levels of nitrosyl complexes of hemoglobin (NO-Hb) and cGMP levels
were measured by electron spin resonance spectroscopy and enzyme immunoassay. In
addition the formation of free NO was determined by confocal microscopy as well as
intracellular nitrite and S-nitrosothiols by chemoluminescence analysis. NO was released
from nitrite in cell culture in an oxygen-dependent manner. Application of specific inhibitors
of the respiratory chain, p450, NO synthases (NOS) and xanthine oxidoreductase (XOR)
showed that all four enzymatic systems are involved in the release of NO, but more
than 50% of NO is released via the mitochondrial pathway. Only NO released by
mitochondria activated cGMP synthesis. Cardiomyocytes co-cultured with red blood cells
(RBC) competed with RBC for nitrite, but free NO was detected only in HL-1 cells
suggesting that RBC are not a source of NO in this model. Apart from activation of
cGMP synthesis, NO formed in HL-1 cells diffused out of the cells and formed NO-Hb
complexes. In addition nitrite was converted by HL-1 cells to S-nitrosyl complexes. In HL-1
cardiomyocytes, several enzymatic systems are involved in nitrite reduction to NO but only
the mitochondrial pathway of NO release activates cGMP synthesis. Our data suggest that
this pathway may be a key regulator of myocardial contractility especially under hypoxic
conditions.
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INTRODUCTION
For decades nitrite and nitrate were thought to be the stable
end products of nitric oxide (NO) produced by various isoforms
of NO synthase (NOS). However, this concept became outdated
when it was recognized that, under hypoxic conditions, nitrite can
be reduced back to NO (Zweier et al., 1995; Lepore et al., 1999;
Cosby et al., 2003; Vanin et al., 2007; van Faassen et al., 2009).
Nitrite-derived NO creates a number of effects, for example
increased levels of nitroso species, alters redox status and induces
protein modifications (Dezfulian et al., 2007, 2009; Perlman et al.,
2009). These effects may be involved in the cytoprotective effects
of nitrite seen inmodels of local ischemia/reperfusion (I/R) injury
in the heart, liver and brain (Lu et al., 2005; Jung et al., 2006;
Bryan et al., 2008; Calvert and Lefer, 2009). Cytoprotection is
attributed to the reduction of nitrite to NO and consequent acti-
vation of cGMP synthesis (Shiva and Gladwin, 2009), which leads
to vasodilation and thus, better perfusion and increased oxygen
supply (Wolin, 2009).
However, the mechanisms by which endogenous or exoge-
nous nitrite is reduced to NO are still under discussion. One
potential pathway occuring in blood is the reduction of nitrite by
hemoglobin (Hb) in red blood cells (RBC). Cosby et al. suggested
that nitrite-derived NO diffuses from the RBC into the smooth
muscle cells of the vasculature and activates nitrite-mediated
vasodilation (Cosby et al., 2003). Recently, however, it was sug-
gested that not NO but another nitrogen species, N2O3, forms
in RBCs diffuses into the tissues and induces vasodilation (Basu
et al., 2007b). Lundberg et al. showed that the reduction of nitrite
to NO depends on the predominant partial pressure of oxygen in
the blood; lower oxygen levels facilitate NO release (Lundberg and
Weitzberg, 2005). Hb seems to follow an allosteric regulation of
nitrite reduction, showing the best nitrite reductase performance
at 50% saturation with oxygen (Rassaf et al., 2007; van Faassen
et al., 2009).
Another pathway of nitrite reduction other than the RBC
pathway is mediated via parenchymal cells in tissues. Various
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intracellular enzymes have been identified to possess nitrite
reductase activity, for example xanthine oxidoreductase (XOR)
(Webb et al., 2008) andNOS (van Faassen et al., 2009). Alsomito-
chondria can rapidly reduce nitrite to NO (Kozlov et al., 1999). It
has been shown that NO reduced from nitrite by mitochondria
in turn reversibly inhibits mitochondrial respiration (Nohl et al.,
2000). However, it is not known whether or not this NO pool may
escape from mitochondria and activate other signaling pathways.
Apart from regulation of vascular tonus, NO plays an impor-
tant role in the cardiovascular system to maintain cardiac func-
tion (Rastaldo et al., 2007) via activation of cGMP synthesis in a
dose-dependent manner. Under physiologic conditions endothe-
lial and neuronal NOS play an important role in cardiac function.
The inhibition of NO synthesis catalyzed by NOS under normoxic
conditions induces cardiac remodeling (hypertrophy), which is
independent of the systemic hemodynamic effects of NO (Sanada
et al., 2003). Nitrite represents a NOS-independent NO-source
that becomes effective under hypoxic conditions. Nitrite, how-
ever, represents a NOS-independent NO-source that becomes
effective under hypoxic conditions like I/R. Previously it was
shown that the reduction of nitrite to NO in heart homogenate
is nearly fully inhibited by myxothiazol, a specific inhibitor of
the mitochondrial respiratory chain at complex III (Kozlov et al.,
2005). However, the impact of this pathway on the bioactiva-
tion of nitrite in cardiomyocytes has not been addressed in the
literature.
The aim of this study was to clarify the impact of mitochon-
dria on nitrite reduction in HL-1 cardiomyocytes under hypoxic
conditions.
MATERIALS AND METHODS
PREPARATION OF HL-1 CELLS AND RBC
HL-1 cardiomyocytes were used in this study. Cells were cultured
under a 5% CO2 atmosphere in Claycomb medium (Sigma, St.
Louis, USA) supplemented with 10% fetal bovine serum (Lonza,
Basel, Switzerland), 4mM L-glutamine (Sigma, St. Louis, USA),
100 U/ml penicillin (Sigma, St. Louis, USA), 100µg/ml strep-
tomycin (Sigma, St. Louis, USA), and 100µM norepinephrine
(Sigma, St. Louis, USA). Cells were seeded in 24-well cell cul-
ture plates precoated with 25µg/ml fibronectin and 0.02% gelatin
solution and cultivated until confluent.
To isolate human RBC, whole blood was centrifuged at 1600 g
for 10min, plasma and buffy-coat discarded and the remain-
ing RBC washed twice with phosphate buffered saline (PBS).
RBC were then diluted with PBS accordingly and counted on a
Cell-Dyn 3700 (Abbott, Switzerland) before use.
EXPERIMENTAL SETUP
Determination of nitrite-derivedNO-release from HL-1 cells
Experiments were performed in a gas-tight glove box, which
allowed to study nitrite reduction under various oxygen concen-
trations (from 21% to <1%O2). All solutions were deoxygenated
with nitrogen prior to experiment. Twenty-four-well cell cul-
ture plates with confluent HL-1 cells (approx. 250,000 cells/well)
were transferred into the glove box containing nitrogen atmo-
sphere. In selected experiments HL-1 cells had been preincubated
under 21% oxygen for 1 h with either 10µMmyxothiazol, 10mM
potassium cynide, 1mM allopurinol, 300µMN-nitro-L-arginine
methyl ester (L-NAME) or 500µM methyrapone. The following
procedures were performed inside the glove box: to measure NO-
Hb, the cell medium was exchanged with diluted RBC in PBS and
cells treated with 50µM nitrite or PBS as control. For analysis of
cGMP synthesis medium was exchanged with PBS, followed by
addition of 50µM nitrite or PBS. PBS contained 1mM of the
phosphodiesterase inhibitor (MacArthur et al., 2007) isobutyl-
methylxanthin (IBMX) to prevent cGMP degradation. Cells were
then incubated under hypoxic conditions on a shaker at 37◦C for
1 h. Afterwards, the supernatant was withdrawn for analyses of
NO-Hb and cGMP, the remaining cells were lysed by sonification
in 500µl lysis reagent provided with the enzyme immunoas-
say for detection of cGMP (GE Healthcare, Fairfield, USA) and
the lysates stored for quantification of intracellular nitrite and
nitroso species. Protein content of the lysates was determined
for normalization by BCA protein assay (Pierce, Rockford, USA).
In selected experiments NO-gas was used as a positive control.
Physiological saline was purged with NO gas (Messer, Austria)
for 15min. NO concentration was determined with a NO elec-
trode (World Precision Instruments Ltd., USA) and was 1mM in
average.
EPR SPECTROSCOPY
The EPR spectra from frozen samples were recorded in a
Miniscope MS 2000 (Magnettech Ltd., Berlin, Germany) at liq-
uid nitrogen temperature with the following settings: microwave
frequency 9.429 GHz, microwave power 30mW, modulation
frequency 100 kHz and modulation amplitude 6G.
CONFOCALMICROSCOPY
The detection of NO production in living cells was performed
using the NO-sensitive fluorescent dye 4-Amino-5-methylamino-
2′,7′-difluorofluorescein diacetate (DAF-FM diacetate; Molecular
Probes, Carlsbad, CA). DAF-FMdiacetate is nitrosated byNO and
is a reasonable indication for NO. HL-1 cells or RBC were loaded
with 10µMDAF-FM diacetate and incubated for 30min at 37◦C.
Afterwards, 50µM of NaNO2 were added and cells were incu-
bated for another 30min at 37◦C under anaerobic conditions in
an incubator at <1% oxygen. Imaging was performed with an
inverted confocal microscope (LSM 510, Zeiss, Germany) with
excitation/emission maxima of 495/515 nm, 63× oil immersion
objective and 2.0 scan zoom.
ANALYSIS OF NITRITE AND NITROSO SPECIES
Nitrite and nitroso species in cell lysates were measured using a
triiodide-based reductive chemiluminescence method with a NO
analyzer (model 280, Seivers, Boulder, USA). To determine the
levels of nitrite and nitroso species two aliquots of each sample
were analyzed, as previously described (MacArthur et al., 2007).
The first aliquot was directly injected into the triiodide reagent
to measure nitrite, the second was incubated for 10min with
acidified sulfanilamide (0.5% vol:vol) to eliminate nitrite before
injected into the triiodide reagent. Since the second measure-
ment represents the signal from nitroso species, the compari-
son of both peaks provides an accurate method for measuring
nitrite.
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cGMPMEASUREMENT
cGMP levels in HL-1 cells were measured by enzyme immunoas-
say (cGMP EIA; GE Healthcare, Fairfield, USA) according to
protocol 3 of the manufacturer’s instructions. Briefly, cell cul-
ture supernatants were aspirated and adherent cells lysed in the
lysis reagent provided. Samples were acetylated prior to perform-
ing the assay. Optical density (405 nm) was measured by a plate
reader (Tecan, Männedorf, Switzerland) and the concentration of
cGMP was calculated from a standard curve produced from serial
dilutions of acetylated cGMP solutions. All standards and samples
were assayed in duplicate.
DATA PRESENTATION AND STATISTICS
Data represent mean ± SD. Significance was calculated using
One-Way ANOVA test with post-hoc LSD (least significant differ-
ence) test.
RESULTS
Under hypoxic conditions NO reacts with Hb yielding nitrosyl
complexes of hemoglobin (NO-Hb) with characteristic electron
spin resonance spectra shown in the inset of Figure 1A. The
baseline level of NO-Hb in RBC was doubled when RBC were
incubated with nitrite, showing that RBC are well able to con-
vert nitrite to NO. Co-culture with HL-1 cells led to a further
significant increase in NO-Hb levels, indicating the significant
portion of NO derived fromHL-1 cells (Figure 1A). It also clearly
demonstrated that the NO formed in HL-1 cells is released from
the cells. Variation of the RBC:HL-1 ratio shows the relative con-
tribution of RBC and HL-1 cells to NO formation (Figure 1B).
A RBC:HL-1 ratio of 166:1 was chosen as it showed the highest
difference between RBC and HL-1 derived NO. NO-Hb forma-
tion in both RBC and HL-1 cells was dependent on the partial
pressure of oxygen (Figure 1C). The provision of free avail-
able NO, however, depends predominantly on parenchymal cells.
The incubation of HL-1 cells with nitrite led to an increase
in intracellular NO levels as revealed by confocal microscopy
using the NO specific indicator dye DAF-2DA. In contrast, free
NO was not detected in RBC as the fluorescence of RBC incu-
bated with nitrite did not change compared to untreated control
(Figure 2A).
Logically, the NO formed in cardiomyocytes has two major
functions. A portion of NO diffusing out of cardiomyocytes
may contribute to the regulation of vascular tonus and another
portion may activate cGMP synthesis regulating myocardial con-
tractility. The release of NO was determined by the formation
of NO-Hb complexes in RBC co-cultured with HL-1 cells and
cGMP levels were determined directly in HL-1 cells. To clarify
the origin of nitrite-derived NO contributing to the formation
of NO-Hb and cGMP synthesis, HL-cells were preincubated with
various specific inhibitors, allowing definition of the impact of
the respective enzymes. Regarding NO release and NO-Hb for-
mation, all inhibitors used decreased the NO-Hb signal. However,
the mitochondrial inhibitor myxothiazol had the most prominent
effect, decreasing NO-Hb levels by 60%. Allopurinol, L-NAME
andmethyrapone, inhibitors of XOR, NOS and cytochrome P450,
respectively, contributed to the formation of NO-Hb, although
significantly less than mitochondria (Figure 2B).
FIGURE 1 | (A) NO production from RBC and in co-culture with HL-1 cells
under hypoxic conditions with and without 50µM nitrite. (A) Both RBC and
HL-1 cells are capable of nitrite reduction. Left set of bars shows the
RBC-mediated release of NO from nitrite. Right set of bars represents data
from co-culture of RBC with HL-cells in a RBC:HL-1 ratio of 166:1
(∗p < 0.005, ∗∗∗p < 0.001 compared to the respective group without nitrite,
###p < 0.001, compared to RBC with nitrite). Inset in 1 (A) shows typical
EPR spectrum of NO-Hb complexes. (B) The relative contribution of both
pathways depends on both nitrite concentrations and the RBC:HL-1 ratio.
A ratio of 166:1 and a nitrite concentration of 50µM were chosen for all
other experiments as these conditions showed the highest difference
inNO-signals with and without HL-1 cells. ∗p < 0.05, ∗∗∗p < 0.001 RBC vs.
RBC + HL-1 of the same group. (C) Oxygen-dependence of NO-Hb signal.
RBC and in co-culture with HL-1 cells were incubated with 50µM nitrite
under various oxygen concentrations. ∗p < 0.001, NO-Hb signals with and
without HL-1 cells. p < 0.001, compared to RBC + HL-1 at 0% oxygen.
#,##p < 0.05 and p < 0.01, respectively, compared to RBC at 0% oxygen.
The impact of these enzymes on nitrite-dependent cGMP for-
mation was investigated in a similar way. cGMP synthesis in HL-1
cells stimulated by nitrite-derived NO was fully prevented by
myxothiazol while other inhibitors had no effect (Figure 3A). NO
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FIGURE 2 | (A) Analysis of free NO using a NO-specific dye and confocal
microscopy. HL-1 cells or RBC were loaded with 10µM DAF-FM and
incubated for about 30min at 37◦C. Afterwards, 50µM of NaNO2 were
added and cells were incubated for another 30min at 37◦C under anaerobic
conditions. Free NO could only be detected in HL-1 cells but not in RBC.
(B) Influence of various inhibitors on NO-Hb signals of RBC in co-culture
with HL-1 cells determined by EPR analysis. Myxothiazol, an inhibitor of
complex III of the respiratory chain, reduced NO-signal by 60%, while all
inhibitors reduced NO-Hb levels by approx. 25%. ∗∗∗p < 0.001, compared
to HL-1 cells incubated with 50µM nitrite. #p < 0.05, compared to RBC
incubated with 50µM nitrite.
gas-saturated saline, used as a positive control, led to significant
increase in cGMP production. However, NO-mediated guanylyl
cyclase (GC) activation was influenced by neither myxothiazol
nor any of the other inhibitors (Figure 3B).
Chemoluminescence analysis showed that incubation of HL-
1 cells with 50µM nitrite led to a drastic increase in intracellular
nitrite (Figure 3C) and nitroso species (Figure 3D) levels. In con-
trast to NO-Hb and cGMP, nitroso species formation was not
sensitive to myxothiazol.
DISCUSSION
In the past years it has been demonstrated that nitrite represents
a storage pool of NO which can be activated, especially under
hypoxic conditions. As nitrite reduction occurs both in blood Hb
and tissue, we investigated the process of exogenous nitrite reduc-
tion in monocultures of HL-1 cells and RBC and in a co-culture
of these two cell types. Since Hb is itself a nitrite reductase, RBC
were incubated with and without nitrite to determine the RBC-
dependent nitrite reduction. The free radical NO binds efficiently
to deoxy-Hb in RBC, yielding the characteristic triplet spectrum
of this NO-Hb complex. The formation of NO-Hb complexes
in RBC incubated with nitrite reflects diffusion of nitrite into
RBC and it reduction to NO. It has been demonstrated in the
literature that nitrite reduction is oxygen-dependent. Figure 1C
shows NO-Hb signals at anaerobic conditions as well as at oxy-
gen concentrations typical for arterial (12.5% O2) and venous
(5% O2) blood. In both RBC and co-culture with HL-1 cells,
NO-Hb signals are reduced with a decrease in oxygen. There are
two explanations for this finding: first, activities of nitrite reduc-
tases decrease with increases in oxygen or, second, Hb becomes
oxygenated and reacts with NO to form methemoglobin rather
than NO-Hb. In any case, anaerobic conditions yield the high-
est amounts of nitrite-derived NO and thus, further experiments
were performed under anaerobic conditions. In cardiomyocytes,
the ability of nitrite to diffuse into HL-1 cells was confirmed
directly by determination of intracellular nitrite levels in HL-1 cell
lysates (Figure 3D).
It has previously been shown that NO diffuses from diverse
parenchymal cells into the blood to form NO-Hb complexes in
RBC, but NO bound to Hb does not diffuse back to parenchymal
cells (Kozlov et al., 2001). Consequently, we assumed that deter-
mination of NO-Hb complexes in our model is a measure of total
NO-production in RBC plus HL-1 cells. In fact, addition of HL-1
cells to a RBC suspension increased nitrite mediated NO-Hb for-
mation due to an additional portion of NO reduced in HL-1 cells.
An increase in the RBC:HL-1 ratio results in an increase of the NO
portion formed inHL-1 cells and reduced the NOportion coming
from RBC. This shows that both RBC- and HL-1 mediated path-
ways have a distinguishable contribution to total NO production
determined by NO-Hb levels. Also, the difference in NO-Hb lev-
els between coculture of HL-1 cells and Hb and Hb alone is the
NO formed in HL-1 cells. In this experimental model we found
that free NO is only detectable in cardiomyocytes but not in RBC.
This was shown by confocal microscopy combined with using the
fluorescent dye DAF used to determine free NO in RBC andHL-1
cells upon treatment with nitrite. Increased DAF fluorescence was
clearly detected in HL-1 cells but not in RBC, suggesting that free
NO only occurs in HL-1 cells. This suggests that NO is tightly
bound to Hb inside RBC. The lack of free NO in RBC seems to
be in contradiction to the fact that RBC-mediated nitrite reduc-
tion contributes to vasodilation. However, this contradiction was
satisfactorily explained in the recent publication of Basu et al. who
suggested that N2O3, not NO, is formed in RBC and is the active
mediator of vasodilation (Basu et al., 2007a).
The intracellular mechanisms of nitrite bioactivation in HL-1
cells were investigated by using inhibitors of various enzymes
with distinct nitrite reductase activity. Specific inhibitors for
XOR, complex III of the mitochondrial electron transport chain,
cytochrome P450 and NOS were used. Cells were incubated with
inhibitors prior to the addition of RBC which served as NO detec-
tion reagent. Thus, the effects of these inhibitors on the NO-Hb
signal were only HL-1 dependent. All inhibitors reduced NO
release, seen as lowered NO-Hb levels, but to various extents.
The mitochondria-specific inhibitor myxothiazol decreased NO
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FIGURE 3 | (A) GMP levels in HL-1 incubated with 50µM nitrite under
hypoxic conditions. cGMP production was completely inhibited by
myxothiazol, suggesting that NO derived from nitrite reduction in
mitochondria is predominately responsible for cGMP synthesis. Controls are
untreated HL-1 cells, Nitrite indicates HL-1 cells treated with 50µM nitrite, all
other groups were treated with nitrite and with one of the following
inhibitors: Myxo, Myxothiazol; Allo, Allopurinol; NAME, N-nitro-L-arginine
methyl ester; Met, Methyrapone. (B) cGMP levels in HL-1 cells incubated
with 50µM NO under hypoxic conditions. GC activation by NO-gas was not
influenced by either myxothiazol or any other inhibitor, demonstrating that
nitrite reduction via mitochondria is predominately responsible for cGMP
synthesis. Controls are untreated HL-1 cells, NO indicates HL-1 cells treated
with 50µM nitritc oxide, all other groups were treated with NO and with one
of the following inhibitors: Myxo, Myxothiazol; Allo, Allopurinol; NAME,
N-nitro-L-arginine methyl ester; Met, Methyrapone. ∗∗p < 0.01, ∗∗∗p < 0.001.
Intracellular levels of nitrite (C) and nitroso species (D) in HL-1 cells. Controls
are untreated HL-1 cells, Nitrite indicates HL-1 cells treated with 50µM
nitrite, Myxo represents HL-1 cells incubated with 50µM nitrite preincubated
with myxothiazol. Cell lysates were analysed by a Sievers NOA280i
chemiluminescence analyser using the tri-iodide method to determine nitrite.
For analysis of nitroso species a second sample was treated with acidified
sulfanilamide to eliminate nitrite. ∗∗∗p < 0.001 vs. control.
signal by 60%. This is in line with the fact that mitochondria
contribute to nitrite reductase activity in heart homogenates by
approx. 80% (Kozlov et al., 2003). However, NO-Hb levels were
not reduced to baseline levels of untreated cells, suggesting that
there are additional pathway(s) of NOproduction. As allopurinol,
NAME and methyrapone reduced NO-signals by 25% each, this
indicates other active mechanisms. According to Dr. Claycomb,
who established the HL-1 cell line, these cells should contain
myoglobin (Mb) comparable to primary cardiomyocytes (pri-
vate communication). Mb is a potent nitrite reductase in the
heart (Shiva et al., 2007) whose impact was not investigated in
this study. However, Shiva et al. used ferricyanide to oxidize Mb
in heart homogenate which led to decreased NO production.
Ferricyanide is an unspecific one electron acceptor interacting
also with the respiratory chain of mitochondria (Krasnikov et al.,
1997). Thus, both nitrite and ferricyanide are reduced accepting
electrons from the respiratory chain. Consequently, the effects
of ferricyanide may be due to the inhibition of nitrite reduc-
tion by the respiratory chain. Thus, ferricyanide might not be
suitable to distinguish between Mb-mediated and mitochondria-
mediated nitrite reduction. On the other hand there are specific
inhibitors of the mitochondrial respiratory chain, which do not
react with Mb, for instance myxothiazol. In our previous publica-
tion we have shown that myxothiazol nearly completely inhibits
nitrite reduction to NO in heart homogenate. This suggests
that mitochondria are responsible for nitrite reduction in heart
homogenate.
Another situation is demonstrated in the paper of Totzeck
et al. (2012). They showed that Mb in SMC is involved in nitrite
reduction and vasodilation. This suggests that the data from
heart homogenate reflect nitrite reduction in cardiomyocytes (the
mayor cell type contributing to heart homogenate), which is likely
relevant for the regulation of myocardial contractility and Mb in
SMC for vascular tonus.
Beside Mb, several studies showed that XOR also is an
important nitrite reductase in the heart. McNulty et al. showed
that in RBC-free heart tissue, nitrite consumption could be
blocked by 40% by allopurinol (McNulty et al., 2008) but
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no mitochondria-specific inhibitor was tested in the study. One
also has to keep in mind that allopurinol acts as an antioxidant as
well, thus also inhibiting intracellular oxidative processes. Baker
et al. demonstrated that both oxypuinol and diphenyleneiodo-
nium (DPI), a non-specific flavoprotein inhibitor, inhibited
nitrite-mediated cardioprotection (Baker et al., 2007). As DPI
also inhibits mitochondrial complex I (Li and Trush, 1998), the
reduction in cytoprotection might be due to reduced nitrite
bioactivation by mitochondria. Irrespectively of the exact mech-
anism of allopurinol, we show that, in our model, mitochondria
are the major contributor to the generation of diffusible NO.
Although mitochondria were only partially responsible for the
generation of diffusible NO, they were the only NO source acti-
vating cGMP synthesis; myxothiazol completely inhibited cGMP
synthesis and other inhibitors had no effect. This finding suggests
that NO by mitochondria-mediated nitrite reduction is predom-
inately responsible for cGMP synthesis in HL-1 cells. Zielinska
et al. demonstrated that fluoroactetate, a metabolic inhibitor
specifically affecting astrocytic mitochondria, inhibited cGMP
synthesis by about 50% (Zielinska et al., 2007). An intracellular
association of mitochondria and GC could explain that cGMP
synthesis, but not NO-Hb signals, were completely blocked by
mitochondrial inhibition.
To exclude the possibility that myxothiazol inhibited not
only nitrite reduction, but also NO-mediated cGMP synthe-
sis, we used pure NO as a control. GC activation by NO-
gas was not influenced by either myxothiazol or any other
inhibitor, showing the predominant contribution of mitochon-
dria to nitrite bioactivation in cardiomyocytes under hypoxic
conditions. These data suggest that the pathway responsible for
stimulation of cGMP synthesis in cardiomyocytes was exclusively
mitochondria-dependent. In addition, it has been shown that
myxothiazol can also induce superoxide production in the mito-
chondrial matrix. Myxothiazol-derived superoxide may cause
oxidation of NO produced in the mitochondria. However,
myxothiazol did not inhibit cGMP production in NO-gas treated
cells. These data may indicate that the nitrite reduction in the
electron transfer chain occurs downstream of the myxothiazol
binding site. This could point to complex IV, cytochrome c oxi-
dase, which has recently been identified as a nitrite reductase
(Castello et al., 2006).
Since NO has been cited to inhibit mitochondrial respiration
nitrite reduction via complex IV the inhibition of this com-
plex would initiate auto-regulation. Under hypoxic conditions
nitrite reduction would continue until critical levels of NO will
be reached to block the reaction at the same site.
We assume that this mitochondria-dependent increase in
cGMP levels contributes to the regulation of myocardial contrac-
tility under hypoxic conditions and to cytoprotection (Cauwels
et al., 2009). In contrast, formation of nitroso species upon nitrite
treatment was not affected by myxothiazol. This suggests that
nitroso compounds are formed from nitrite, not from NOwithin
HL-1 cells.
In conclusion, in this study we showed in vitro that both RBC
andHL-1 cardiomyocytes mediated the reduction of nitrite to NO
under hypoxic conditions. RBC-mediated nitrite reduction did
not contribute to cGMP synthesis in HL-1 cells. cGMP produc-
tion in cardiomyocytes was completely inhibited by myxothiazol,
a specific inhibitor of mitochondria, while inhibitors of XOR,
NOS, and p450 had no effect. The effect of myxothiasol was
not due to inhibition of cGMP synthesis itself, suggesting that
mitochondria trigger nitrite-mediated cGMP synthesis in car-
diomyocytes. Our data suggest that this pathway may be a key
regulator of myocardial contractility, especially under hypoxic
conditions.
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